SI2737906T1 - Terapevtska cepiva - Google Patents
Terapevtska cepiva Download PDFInfo
- Publication number
- SI2737906T1 SI2737906T1 SI200931844T SI200931844T SI2737906T1 SI 2737906 T1 SI2737906 T1 SI 2737906T1 SI 200931844 T SI200931844 T SI 200931844T SI 200931844 T SI200931844 T SI 200931844T SI 2737906 T1 SI2737906 T1 SI 2737906T1
- Authority
- SI
- Slovenia
- Prior art keywords
- conjugate
- peptide
- gly
- val
- mixture according
- Prior art date
Links
- 229940021747 therapeutic vaccine Drugs 0.000 title claims 2
- 108010033276 Peptide Fragments Proteins 0.000 claims abstract 4
- 102000007079 Peptide Fragments Human genes 0.000 claims abstract 4
- 208000026278 immune system disease Diseases 0.000 claims abstract 4
- HGNRJCINZYHNOU-LURJTMIESA-N Lys-Gly Chemical group NCCCC[C@H](N)C(=O)NCC(O)=O HGNRJCINZYHNOU-LURJTMIESA-N 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims abstract 3
- 108010064235 lysylglycine Proteins 0.000 claims abstract 3
- 125000004122 cyclic group Chemical group 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims 6
- 229910052748 manganese Inorganic materials 0.000 claims 5
- 239000011572 manganese Substances 0.000 claims 5
- 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 claims 4
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims 2
- 201000002491 encephalomyelitis Diseases 0.000 claims 2
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 229920000057 Mannan Polymers 0.000 abstract 2
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 abstract 1
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 102000006386 Myelin Proteins Human genes 0.000 abstract 1
- 108010083674 Myelin Proteins Proteins 0.000 abstract 1
- 102000016202 Proteolipids Human genes 0.000 abstract 1
- 108010010974 Proteolipids Proteins 0.000 abstract 1
- 210000005012 myelin Anatomy 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/10—Animals modified by protein administration, for non-therapeutic purpose
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0325—Animal model for autoimmune diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Rehabilitation Therapy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (17)
- Terapevtska cepiva Patentni zahtevki1. Konjugat, ki vsebuje: (i) manan; in (ii) vsaj en epitop, ki vsebuje delec peptida mielin oligodendrocit glikoprotein (MOG), kjer je omenjeni delec peptida v ravni ali razvejani obliki; kjer epitop vsebuje peptid MOG35.55, ki odgovarja peptidu zaporedja SEQ ID NO. 2: H-Met-Glu-Val-Gly-Trp-Tyr-Arg-Pro-Pro-Phe-Ser-Arg-Val-Val-His-Leu-Tyr-Arg-Asn-Gly-Lys-OH [SEQ ID NO. 2] v ravni ali razvejani obliki; in kjer je omenjeni epitop povezan z mananom preko mostička [(Lys-Gly)s].
- 2. Konjugat po zahtevku 1, kjer je manan reduciran manan.
- 3. Konjugat po zahtevku 1, kjer je manan oksidiran manan.
- 4. Konjugat po kateremkoli zahtevku od 1 do 3, kjer je peptid zaporedja SEQ ID NO. 2 v ravni obliki.
- 5. Konjugat po kateremkoli predhodnem zahtevku, kjer sta z mananom povezana dva ali več epitopa ali njuna ciklična nasprotna dela.
- 6. Konjugat po zahtevku 5, kjer so epitopi različni.
- 7. Mešanica, ki vsebuje dva ali več konjugatov, po kateremkoli izmed zahtevkov od 1 do 6.
- 8. Mešanica po zahtevku 7, kjer so konjugati različni.
- 9. Farmacevtski pripravek, ki vsebuje konjugat po kateremkoli zahtevku od 1 do 6 ali mešanico po zahtevku 7 ali zahtevku 8 in farmacevtsko sprejemljiv nosilec, redčilo ali ekscipient.
- 10. Konjugat po kateremkoli zahtevku od 1 do 6 ali mešanica po zahtevku 7 ali po zahtevku 8, za uporabo v medicini.
- 11. Uporaba konjugata po kateremkoli zahtevku od 1 do 6 ali mešanice po zahtevku 7 ali po zahtevku 8 v pripravi zdravila za zdravljenje imunske motnje.
- 12. Uporaba po zahtevku 11, kjer je imunska motnja avtoimunska bolezen.
- 13. Uporaba po zahtevku 11, kjer je motnja multipla skleroza (MS) ali eksperimentalni avtoimunski encefalomielitis (EAE).
- 14. Uporaba konjugata po kateremkoli zahtevku od 1 do 6 v testih ex vivo, kot sredstva za osvetlitev, ki so zmožna uravnavati eksperimentalni avtoimunski encefalomielitis (EAE) ali multiplo sklerozo.
- 15. Postopek priprave konjugata po kateremkoli zahtevku od 1 do 6, kjer omenjeni postopek obsega naslednje korake: (i) reagiranje epitopa, ki vsebuje delec peptida mielin oligodendrocit glikoproteina (MOG), kjer je omenjeni delec peptida v ravni ali razvejani obliki, kjer epitop vsebuje peptid MOG35.55, ki odgovarja peptidu zaporedja SEQ ID NO. 2: H-Met-Glu-Val-Gly-Trp-Tyr-Aig-Pro-Pic>-Phe-Ser-Aig-Val-Val-His-Leu-Tyi-Afg-Asn-Gly-Lys-OH [SEQ ID NO. 2] v ravni ali razvejani obliki, s peptidnim mostičkom [(Lys-Gly)s] ; (ii) reagiranje produkta nastalega v koraku (i) z oksidiranim mananom; in (iii) neobvezno redukcijo produkta nastalega v koraku (ii), da tvorimo konjugat z reduciranim mananom.
- 16. Cepivo, ki vsebuje konjugat po kateremkoli zahtevku od 1 do 6 ali mešanico po zahtevku 7 ali po zahtevku 8.
- 17. Konjugat po kateremkoli zahtevku od 1 do 6 ali mešanica po zahtevku 7 ali po zahtevku 8, za uporabo v zdravljenju imunske motnje.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0801424A GB0801424D0 (en) | 2008-01-25 | 2008-01-25 | Therapeutic vaccines |
| GB0802405A GB0802405D0 (en) | 2008-02-08 | 2008-02-08 | Therapeutic vaccines |
| GR20080100151A GR1006998B (el) | 2008-02-29 | 2008-02-29 | Ανοσοκυριαρχοι επιτοποι των μυελινικων πρωτεϊνων mbp, mog και plp συζευγμενοι στην ανηγμενη και οξειδωμενη μαννανη μεσω της γεφυρας [(lys-gly)n] για την θεραπεια της σκληρυνσης κατα πλακας. |
| EP14156495.5A EP2737906B1 (en) | 2008-01-25 | 2009-01-22 | Therapeutic vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2737906T1 true SI2737906T1 (sl) | 2018-08-31 |
Family
ID=40785428
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200931490A SI2240200T1 (sl) | 2008-01-25 | 2009-01-22 | Terapevtski, z mananom povezan peptid, mileinskega bazičnega proteina MBP83-99 |
| SI200931844T SI2737906T1 (sl) | 2008-01-25 | 2009-01-22 | Terapevtska cepiva |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200931490A SI2240200T1 (sl) | 2008-01-25 | 2009-01-22 | Terapevtski, z mananom povezan peptid, mileinskega bazičnega proteina MBP83-99 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9180174B2 (sl) |
| EP (2) | EP2240200B1 (sl) |
| AU (1) | AU2009207345B2 (sl) |
| CY (2) | CY1117898T1 (sl) |
| DK (2) | DK2240200T3 (sl) |
| ES (2) | ES2669516T3 (sl) |
| HR (2) | HRP20160985T1 (sl) |
| HU (2) | HUE029899T2 (sl) |
| LT (2) | LT2737906T (sl) |
| NO (1) | NO2737906T3 (sl) |
| PL (2) | PL2737906T3 (sl) |
| PT (2) | PT2737906T (sl) |
| SI (2) | SI2240200T1 (sl) |
| TR (1) | TR201807084T4 (sl) |
| WO (1) | WO2009093143A2 (sl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL398077A1 (pl) * | 2012-02-10 | 2012-08-27 | Krzysztof Selmaj | Kompozycja farmaceutyczna oraz zastosowanie kompozycji do wytwarzania leku, do podawania naskórnego, do leczenia stwardnienia rozsianego |
| GR20170100262A (el) * | 2017-06-12 | 2019-03-20 | Ιωαννης Μηνα Ματσουκας | Κυκλικα πεπτιδικα αναλογα της πρωτεϊνης "ολιγοδενδροκυτταρικη μυελινη" και συζευγματα των για την ανοσοθεραπεια της σκληρυνσης κατα πλακας |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2445640A1 (en) * | 2001-03-23 | 2002-10-03 | John Matsoukas | Peptide analogues of myelin basic protein epitopes in the treatment of experimental autoimmune encephalomyelitis (eae) and multiple sclerosis (ms) |
| IL146016A0 (en) | 2001-10-17 | 2002-07-25 | Yeda Res & Dev | Synthetic peptides and dna sequences and compositions comprising them for treatment of multiple sclerosis |
| US8273357B2 (en) | 2004-07-16 | 2012-09-25 | Massachusetts Institute Of Technology | Antigen-carbohydrate conjugates |
| US20070178113A1 (en) * | 2005-11-22 | 2007-08-02 | Backstrom B T | Superantigen conjugate |
-
2009
- 2009-01-22 PT PT141564955T patent/PT2737906T/pt unknown
- 2009-01-22 US US12/864,019 patent/US9180174B2/en active Active
- 2009-01-22 EP EP09703874.9A patent/EP2240200B1/en active Active
- 2009-01-22 TR TR2018/07084T patent/TR201807084T4/tr unknown
- 2009-01-22 SI SI200931490A patent/SI2240200T1/sl unknown
- 2009-01-22 WO PCT/IB2009/000382 patent/WO2009093143A2/en active Application Filing
- 2009-01-22 LT LTEP14156495.5T patent/LT2737906T/lt unknown
- 2009-01-22 HU HUE09703874A patent/HUE029899T2/en unknown
- 2009-01-22 ES ES14156495.5T patent/ES2669516T3/es active Active
- 2009-01-22 ES ES09703874.9T patent/ES2585482T3/es active Active
- 2009-01-22 NO NO14156495A patent/NO2737906T3/no unknown
- 2009-01-22 AU AU2009207345A patent/AU2009207345B2/en active Active
- 2009-01-22 DK DK09703874.9T patent/DK2240200T3/en active
- 2009-01-22 EP EP14156495.5A patent/EP2737906B1/en active Active
- 2009-01-22 SI SI200931844T patent/SI2737906T1/sl unknown
- 2009-01-22 LT LTEP09703874.9T patent/LT2240200T/lt unknown
- 2009-01-22 DK DK14156495.5T patent/DK2737906T3/en active
- 2009-01-22 PL PL14156495T patent/PL2737906T3/pl unknown
- 2009-01-22 HU HUE14156495A patent/HUE037687T2/hu unknown
- 2009-01-22 PT PT97038749T patent/PT2240200T/pt unknown
- 2009-01-22 PL PL09703874.9T patent/PL2240200T3/pl unknown
-
2015
- 2015-10-07 US US14/877,679 patent/US20160095935A1/en not_active Abandoned
-
2016
- 2016-08-02 HR HRP20160985TT patent/HRP20160985T1/hr unknown
- 2016-08-03 CY CY20161100766T patent/CY1117898T1/el unknown
-
2018
- 2018-05-14 HR HRP20180744TT patent/HRP20180744T1/hr unknown
- 2018-05-18 CY CY20181100509T patent/CY1120261T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20160985T1 (hr) | 2016-10-21 |
| HUE037687T2 (hu) | 2018-09-28 |
| AU2009207345A1 (en) | 2009-07-30 |
| NO2737906T3 (sl) | 2018-07-28 |
| HRP20180744T1 (hr) | 2018-06-29 |
| PL2737906T3 (pl) | 2018-09-28 |
| US9180174B2 (en) | 2015-11-10 |
| US20110243981A1 (en) | 2011-10-06 |
| WO2009093143A3 (en) | 2009-11-12 |
| AU2009207345A8 (en) | 2013-08-22 |
| SI2240200T1 (sl) | 2016-11-30 |
| EP2737906A1 (en) | 2014-06-04 |
| EP2737906B1 (en) | 2018-02-28 |
| WO2009093143A2 (en) | 2009-07-30 |
| ES2585482T3 (es) | 2016-10-06 |
| PT2240200T (pt) | 2016-08-08 |
| CY1117898T1 (el) | 2017-05-17 |
| PL2240200T3 (pl) | 2016-12-30 |
| US20160095935A1 (en) | 2016-04-07 |
| CY1120261T1 (el) | 2019-07-10 |
| DK2737906T3 (en) | 2018-05-28 |
| AU2009207345B2 (en) | 2013-11-28 |
| EP2240200B1 (en) | 2016-05-04 |
| DK2240200T3 (en) | 2016-08-22 |
| HUE029899T2 (en) | 2017-04-28 |
| EP2240200A2 (en) | 2010-10-20 |
| LT2240200T (lt) | 2016-09-26 |
| TR201807084T4 (tr) | 2018-06-21 |
| PT2737906T (pt) | 2018-05-28 |
| ES2669516T3 (es) | 2018-05-28 |
| LT2737906T (lt) | 2018-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11472846B2 (en) | Compositions and methods for treating diseases by inhibiting exosome release | |
| US20190008853A1 (en) | Method for treating a protozoal infection | |
| CN103796684B (zh) | 大分子 | |
| EP3773727A1 (en) | Bifunctional small molecules to target the selective degradation of circulating proteins | |
| EP3820489A1 (en) | Compositions and methods for treating diseases by inhibiting exosome release | |
| IL186793A0 (en) | Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease | |
| US20210228494A1 (en) | Drug delivery systems and methods comprising polysialic acid and/or other polymers | |
| McCall et al. | Pathogen-inspired drug delivery to the central nervous system | |
| RU2014101207A (ru) | Новые показания к применению при лечении антителами против il-1-бета | |
| US20220339259A1 (en) | Orally delivered therapeutical composition and use thereof | |
| TW201231067A (en) | End-capped polymers and methods of making the same, pharmaceutical compositions and uses of an effective amount of the end-capped polymers | |
| JP2011503019A5 (sl) | ||
| SI2737906T1 (sl) | Terapevtska cepiva | |
| Mignani et al. | Dendrimer nanoplatforms for veterinary medicine applications: A concise overview | |
| EP4192843A1 (en) | Peptides able to bind angiotensin-converting enzyme 2 (ace2) and medical uses thereof | |
| Lu et al. | Nanotherapeutics for Alleviating Anesthesia‐Associated Complications | |
| JP6857875B2 (ja) | 新規な細胞膜透過性ペプチド | |
| WO2019094868A1 (en) | Biodegradable polymer and use thereof | |
| RU2007120689A (ru) | Композиция, содержащая вирусоподобную частицу (впч) и пептид амилоид-бета | |
| EP4230223A1 (en) | Composition | |
| ES2967696T3 (es) | Factor de crecimiento epidérmico (EGF) y variantes del mismo para tratar o prevenir trastornos desmielinizantes inflamatorios | |
| GR1006998B (el) | Ανοσοκυριαρχοι επιτοποι των μυελινικων πρωτεϊνων mbp, mog και plp συζευγμενοι στην ανηγμενη και οξειδωμενη μαννανη μεσω της γεφυρας [(lys-gly)n] για την θεραπεια της σκληρυνσης κατα πλακας. | |
| Wang | Novel biomaterials for controlled immunomodulatory drug delivery | |
| Yuan | Delivery of Therapeutic Proteins to the Brain | |
| EP4178988A1 (en) | In situ thiol-maleimide crosslinked hydrogel for immune checkpoint blockade delivery |